Meeting
2024 ASCO Genitourinary Cancers Symposium
Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study.
Presenter
Michiel Simon Van Der Heijden, MD, PhD
Department of Medical Oncology, Netherlands Cancer Institute
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Oral Abstract Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04223856
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr LBA530)
DOI
10.1200/JCO.2024.42.4_suppl.LBA530
Abstract #
LBA530
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Breakthrough
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
Speaker: Eiji Kikuchi, PhD
Videos & Slides
2024 ASCO Annual Meeting
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
Speaker: Shilpa Gupta, MD
Videos & Slides
2023 ASCO Annual Meeting
Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.
Speaker: Terence W. Friedlander, MD
Videos & Slides
2023 ASCO Genitourinary Cancers Symposium
Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study.
Speaker: Matthew I. Milowsky, MD, FASCO